NASDAQ : PLYX
Polaryx Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 92.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 2.75M | 1.55M | 1.54M | 1.01M |
| Research & Development | 2.47M | 6.27M | 2.81M | 2.77M |
| Operating Expenses | 5.22M | 7.82M | 4.35M | 3.78M |
| Operating Income | -5.22M | -7.82M | -4.35M | -3.78M |
| Other Non Operating Income (Expenses) | -1.63M | -1.16M | -26.00M | 2.00K |
| Pretax Income | -6.85M | -8.98M | -30.36M | -3.78M |
| Net Income | -6.85M | -8.98M | -30.36M | -3.78M |
| Net Income to Common | -6.85M | -8.98M | -30.36M | -3.78M |
| Shares Outstanding (Basic) | 47.05M | 45.42M | 34.20M | 10.69M |
| Shares Outstanding (Diluted) | 47.05M | 45.42M | 34.20M | 10.69M |
| EPS (Basic) | -0.15 | -0.20 | -0.89 | -0.35 |
| EPS (Diluted) | -0.15 | -0.20 | -0.89 | -0.35 |
| EBIT | -5.22M | -7.82M | -4.35M | -3.78M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 11.54M | 5.14M | 4.62M | 2.00K |
| Cash & Short-Term Investments | 11.54M | 5.14M | 4.62M | 2.00K |
| Prepaid Expenses | 270.00K | 380.00K | 2.31M | |
| Other Current Assets | 27.00K | |||
| Total Current Assets | 11.81M | 5.17M | 5.00M | 2.31M |
| Total Assets | 11.81M | 5.17M | 5.00M | 2.31M |
| Accounts Payable | 683.00K | 470.00K | 72.00K | 473.00K |
| Accrued Expenses | 190.00K | 135.00K | 217.00K | 437.00K |
| Short-Term Debt | 128.00K | |||
| Total Current Liabilities | 873.00K | 605.00K | 289.00K | 1.04M |
| Total Liabilities | 873.00K | 605.00K | 289.00K | 1.04M |
| Common Stock | 5.00K | 5.00K | 4.00K | 4.00K |
| Additional Paid-In Capital | 114.49M | 104.19M | 95.36M | 61.57M |
| Retained Earnings | -103.56M | -99.64M | -90.65M | -60.29M |
| Shareholders' Equity | 10.94M | 4.57M | 4.71M | 1.28M |
| Total Liabilities & Equity | 11.81M | 5.17M | 5.00M | 2.31M |
| Total Debt | 128.00K | |||
| Net Cash (Debt) | 11.54M | 5.14M | 4.62M | -126.00K |
| Net Cash Per Share | 0.25 | 0.11 | 0.14 | -0.01 |
| Filing Date Shares Outstanding | 49.85M | 47.34M | 41.15M | 10.69M |
| Total Common Shares Outstanding | 49.85M | 47.34M | 41.15M | 10.69M |
| Working Capital | 10.94M | 4.57M | 4.71M | 1.28M |
| Book Value Per Share | 0.22 | 0.10 | 0.11 | 0.12 |
| Tangible Book Value | 10.94M | 4.57M | 4.71M | 1.28M |
| Tangible Book Value Per Share | 0.22 | 0.10 | 0.11 | 0.12 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -6.85M | -8.98M | -30.36M | -3.78M |
| Stock-Based Compensation | 632.00K | 4.72M | 2.40M | 3.24M |
| Other Operating Activities | 26.00M | |||
| Change in Accounts Payable | 525.00K | 398.00K | -401.00K | -52.00K |
| Change in Other Net Operating Assets | -117.00K | -82.00K | -220.00K | 421.00K |
| Operating Cash Flow | -5.81M | -3.94M | -2.57M | -173.00K |
| Short-Term Debt Issued | 65.00K | 128.00K | ||
| Total Debt Issued | 65.00K | 128.00K | ||
| Short-Term Debt Repaid | -193.00K | |||
| Total Debt Repaid | -193.00K | |||
| Net Debt Issued (Repaid) | -128.00K | 128.00K | ||
| Issuance of Common Stock | 14.07M | 4.49M | 7.32M | |
| Other Financing Activities | -27.00K | -27.00K | ||
| Financing Cash Flow | 14.05M | 4.47M | 7.19M | 128.00K |
| Net Cash Flow | 8.24M | 522.00K | 4.62M | -45.00K |
| Levered Free Cash Flow | -2.09M | 505.88K | 992.00K | |
| Unlevered Free Cash Flow | -2.09M | 505.88K | 992.00K | |
| Change in Working Capital | 408.00K | 316.00K | -621.00K | 369.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Debt / Equity Ratio | 0.10 | |||
| Net Debt / Equity Ratio | -1.05 | -1.13 | -0.98 | 0.10 |
| Quick Ratio | 13.22 | 8.50 | 15.99 | 0.00 |
| Current Ratio | 13.53 | 8.54 | 17.30 | 2.23 |
| Return on Equity (ROE) | -96.56% | -193.70% | -1,013.73% | |
| Return on Assets (ROA) | -42.52% | -96.12% | -74.36% | |
| Return on Capital Employed (ROCE) | -47.70% | -171.30% | -92.40% | -296.10% |
| Buyback Yield / Dilution | -13.11% | -32.81% | -219.94% |